

# Nicola J Huxley

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/466958/publications.pdf>

Version: 2024-02-01

17  
papers

406  
citations

933447

10  
h-index

1125743

13  
g-index

17  
all docs

17  
docs citations

17  
times ranked

870  
citing authors

#	ARTICLE	IF	CITATIONS
1	A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome. Health Technology Assessment, 2014, 18, 1-406.	2.8	98
2	Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation. Health Technology Assessment, 2017, 21, 1-238.	2.8	83
3	Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model. Health Technology Assessment, 2016, 20, 1-594.	2.8	42
4	A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients. BMC Cancer, 2015, 15, 313.	2.6	37
5	A systematic review and economic evaluation of intraoperative tests [RD-100i one-step nucleic acid amplification (OSNA) system and Metasin test] for detecting sentinel lymph node metastases in breast cancer. Health Technology Assessment, 2015, 19, 1-216.	2.8	33
6	The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation. Health Technology Assessment, 2017, 21, 1-294.	2.8	24
7	The predicted impact and cost-effectiveness of systematic testing of people with incident colorectal cancer for Lynch syndrome. Medical Journal of Australia, 2020, 212, 72-81.	1.7	22
8	Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England. Pharmacoeconomics, 2018, 36, 837-851.	3.3	18
9	The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 5 1-588.	2.8	15
10	Immunosuppressive agents in adult kidney transplantation in the National Health Service: a model-based economic evaluation. Nephrology Dialysis Transplantation, 2017, 32, 1251-1259.	0.7	14
11	Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation. Health Technology Assessment, 2016, 20, 1-324.	2.8	10
12	A systematic review of test accuracy studies evaluating molecular micro-satellite instability testing for the detection of individuals with lynch syndrome. BMC Cancer, 2017, 17, 836.	2.6	9
13	Cost Effectiveness of Cetuximab and Panitumumab for First-Line RAS WT Metastatic Colorectal Cancer. Value in Health, 2016, 19, A154.	0.3	1
14	Cost-Effectiveness of Systematic Testing for Lynch Syndrome in Patients Newly Diagnosed with Colorectal Cancer in the United Kingdom. Value in Health, 2013, 16, A414.	0.3	0
15	What is the Clinical Effectiveness of Erythropoiesis Stimulating Agents for the Treatment of Cancer Treatment-Induced Anaemia?. Annals of Oncology, 2014, 25, iv523.	1.2	0
16	A Cost-Effectiveness Analysis of Erythropoiesis-Stimulating Agents for Treating Cancer-Treatment Induced Anaemia. Annals of Oncology, 2014, 25, iv357.	1.2	0
17	What is the Clinical Effectiveness and Cost- Effectiveness of Erythropoietin-Stimulating Agents for the Treatment of Patients with Cancer-Treatment Induced Anaemia? Insights from Cumulative Meta-Analyses (CMA) and Lessons for Cost-Effectiveness Analyses. Value in Health, 2014, 17, A617.	0.3	0